This review article explores recent advancements in PET/MRI for clinical oncologic imaging.
Radiologists should understand the technical considerations that have made PET/MRI feasible within clinical workflows, the role of PET tracers for imaging various molecular targets in oncology, and advantages of hybrid PET/MRI compared with PET/CT.
To facilitate this understanding, we discuss clinical examples (including gliomas, breast cancer, bone metastases, prostate cancer, bladder cancer, gynecologic malignancy, and lymphoma) as well as future directions, challenges, and areas for continued technical optimization for PET/MRI.
AJR. American journal of roentgenology. 2015 Oct 22 [Epub ahead of print]
Andrew B Rosenkrantz, Kent Friedman, Hersh Chandarana, Amy Melsaether, Linda Moy, Yu-Shin Ding, Komal Jhaveri, Luis Beltran, Rajan Jain
1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016. , 1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016. , 1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016. , 1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016. , 1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016. , 1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016. , 2 Department of Medicine, NYU School of Medicine, New York, NY. , 1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016. , 1 Department of Radiology, NYU School of Medicine, 660 First Ave, 2nd Fl, New York, NY 10016.